1 / 43

Joseph Califano, M.D. Department of Otolaryngology- Head and Neck Surgery Johns Hopkins University Baltimore, MD USA

Surgical Management of the Neck in Head and Neck Cancer. Joseph Califano, M.D. Department of Otolaryngology- Head and Neck Surgery Johns Hopkins University Baltimore, MD USA. General Goals. Review the indications for management of cervical nodal metastasis in head and neck cancer

jared
Télécharger la présentation

Joseph Califano, M.D. Department of Otolaryngology- Head and Neck Surgery Johns Hopkins University Baltimore, MD USA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Surgical Management of the Neck in Head and Neck Cancer Joseph Califano, M.D. Department of Otolaryngology- Head and Neck Surgery Johns Hopkins University Baltimore, MD USA

  2. General Goals • Review the indications for management of cervical nodal metastasis in head and neck cancer • Indications for selective, staging neck dissection • Newer techniques, including sentinel node biopsy

  3. Levels of the Neck II I III VI V IV

  4. Sublevels of the Neck IIB IB IIA IA III VA VI IV VB

  5. Neck Dissection:Terminology • AHNS recommendations favor descriptive terminology to obtain better precision • Neck levels • Structures preserved • Structures sacrificed

  6. Sources of Bias in Literature Regarding Neck Dissection • Almost all data from retrospective analyses • No standard method of identification of levels by pathologist • Both contralateral and ipsilateral necks are reported • Localization of primary sites can be challenging

  7. Neck Dissection • Staging: A variety of selective neck dissections for staging of HNSC with N0 disease • Therapy: Usually a comprehensive neck dissection for known presence of disease

  8. Historical Approach • George Crile’s initial description of neck dissection: • bleeding controlled by clamping of common carotid artery • “softening of the brain” noted postoperatively • Radical neck dissection: removal of • levels I-V • Internal Jugular Vein • Sternocleidomastoid • CN XI

  9. Radical Neck Dissection

  10. Modified Neck Dissection • Modified neck dissection: preservation of one or more of the following if not directly invaded • Internal Jugular Vein • Sternocleidomastoid • CN XI • Submandibular gland, etc. (Bocca et al. 1967) • Comparison of MRND vs. RND regional recurrence • Radical Neck Dissection 13-16% • Modified Neck Dissection 6-9% • Improved shoulder function with CN XI preservation

  11. Neck Dissection With Preservation of the SCM, IJ, and CN XI

  12. Selective vs. Comprehensive/(I-V) Neck Dissection • Removal of a portion of nodal groups based on preferential metastases from known primary site • Lindberg, Cancer, 1972 • Buckley, Head and Neck, 2001 • Primary Rationale: Staging, determination of nodal involvement to guide further therapy, usually radiotherapy or conversion to comprehensive neck dissection (I-V) if intraoperative disease

  13. Selective vs. Comprehensive/(I-V) Neck Dissection • Secondary Rationale: Therapy, clearance of known or suspected nodal disease • Controversy regarding use as therapy for N+ disease • Advantages: clear improvement in postoperative morbidity, particularly in CN XI function

  14. Comprehensive Neck Dissection:Levels I-V • Safe, accepted, traditional means of addressing any N+ neck surgically • Major structures require sacrifice when involved with tumor

  15. Distribution of Nodal Metastases:Oral Cavity • I 30% • II 35% • III 23% • IV 9% • V 2%

  16. Level IV in Oral Cavity Selective Neck Dissection • 16% of patients with oral tongue cancer have isolated positive node in level III or level IV • 8% with isolated level IV node involvement during or after neck dissection • Byers et al. Head and Neck, 1997

  17. Risk of Occult Nodal Metastasis: Oral Cavity • For clinical T1, T2 N0 oral tongue SCC, risk of occult nodal metastasis is ~20%, 50% • Byers, et al, Head and Neck 1998 • Oral Cavity tumor thickness >3-4 mm. predicts elevated risk of occult metastasis >40% • Spiro Am J Surg 1986, • Yuen Head and Neck 2002 • Undissected T1, T2 N0 oral cavity cancer associated with a 50% regional recurrence rate Yuen Head and Neck, 1997

  18. Selective Neck Dissection I-IIIfor oral cavity N0 disease • T2-T4 NO oral cavity • Any T thickness > 0.4 cm • Isolated IIB metastasis rare IIB I IIA III IV

  19. Distribution of Nodal Metastases:Oropharynx • I 10% • II 52% • III 34% • IV 20% • V 7%

  20. Oropharynx: Special Considerations • Isolated level V nodal metastasis extremely rare • Retropharyngeal nodes are a primary nodal drainage site, but not addressed by neck dissection • Radiotherapy often administered for primary and regional control • High risk of bilateral nodal metastasis

  21. Selective Neck Dissection II-IVfor Oropharynx • T2-T4 NO oropharynx • T1N0 controversial • Retropharyngeal nodal basin may be treated with radiotherapy regardless of neck status, obviating need for selective neck dissection to determine therapy IIB IIA III IV

  22. Distribution of Nodal Metastases:Larynx and Hypopharynx • I 2% • II 31% • III 27% • IV 12% • V 2.6%

  23. Selective Neck Dissection Hypopharynx: Considerations • Propensity to bilateral nodal metastasis • Usually presents at advanced stage • Selective Neck dissection used to determine need for radiotherapy in very early stage lesions treated with primary surgical therapy

  24. Selective Neck Dissection Larynx: Considerations • T1 glottic tumors with low potential for cervical metastasis, <10%, selective neck dissection not performed • Supraglottic tumors have a high risk for occult nodal metastasis and bilateral nodal spread • T1, 20% • T2, 40%

  25. Selective Neck Dissection II-IVfor Hypopharynx and Larynx • T2-T4 NO Larynx • If N0 treated with radiotherapy for primary, may be no need for selective neck dissection • T1-T4 NO hypopharynx • If N0 treated with radiotherapy for primary, may be no need for selective neck dissection IIB IIA III IV

  26. Paratracheal Nodal Dissection for Larynx, Hypopharynx • 10 –20 % risk of paratracheal nodal positivity for patients in whom level VI is dissected • Usually associated with contralateral positive nodes • Often associated with subglottic, pyriform apex, cervical esophageal tumors • Postoperative radiotherapy results in a reduced parastomal recurrence for patients with pathologic nodes in level VI

  27. Selective Neck Dissection VIfor selected larynx/hypopharynx/thyroid tumors VI

  28. Postoperative Radiotherapy after Selective Neck Dissection • Patients with any single or multiple nodal metastasis have improved regional control with postoperative radiotherapy (6% vs.36% for single node) • Byers, et al. Head and Neck 1999 (n=517) • Ambrosch, et al., Otolaryngol HNS 2001 (n=503) • Approximately 50% of recurrences were within the dissected field • Approximate 5% improvement in regional control by radiotherapy for pN1 disease

  29. Selective Neck Dissection for clinically N+ Disease: A Controversy • Rationale: Postoperative radiotherapy may achieve control of microscopic/subclinical metastatic disease • Improved functional outcome

  30. Selective Neck Dissection for clinically N+ Disease: A Controversy • Most studies limited, with highly selected group • Anderson et al. Arch Otol HNS, 2002 • 106 patients, 129 necks • 55% N1, 26% N2b • 72% irradiated • 94% control with >2 Y follow up

  31. Selective Lymph Node Sampling • Mentioned in order to be condemned • Positive necks discovered = positive necks missed • Manni et al. Am J Surg 1991 • Sensitivity of less than 50% • Wein et al. Laryngoscope, 2002 • Sensitivity 56%, specificity 70% • Finn S, et al. Laryngoscope. 2002 Apr;112(4):630-3.

  32. Sentinel node biopsy • 99Tc labeled colloid +/- blue colloid dye injected into tumor • Preoperative imaging, hand held gamma probe, visual identification used to dissect sentinel lymph node (initial draining node)

  33. Sentinel Node Biopsy • 10-15 reports in literature • Largest series is a collection of multicenter data (Ross et al., Ann Surg Oncol 2002) • 316 necks evaluated • Sentinel node identified in 95% • 76 positive necks • 90% sensitivity

  34. Sentinel Node Biopsy: Pitfalls • Only accessible tumors can be injected preoperatively, e.g. oropharynx, oral cavity • Additional cost, need for second procedure • Morbidity/cost analysis vs. selective neck dissection • 10% of occult metastases that may be detected by selective neck dissection remain undiagnosed • Should be performed in prospective clinical trials

  35. Neck Dissection After Chemotherapy and/or Radiation • Most series advocate neck dissection in N2 or greater disease, regardless of clinical response • Residual tumor found in neck in over 30% of N2 necks and 50% of N3 necks after chemoradiation • Laryngoscope. 2007 Jan;117(1):121-8. Sewall GK, et al. • Residual disease may not correlate with response • Recurrences after chemoradiation are often unresectable

  36. Liauw SL, Amdur RJ, Morris CG, Werning JW, Villaret DB, Mendenhall WM. Isolated neck recurrence after definitive radiotherapy for node-positive head and neck cancer: Salvage in the dissected or undissected neck. Head Neck. 2007 Feb 1

  37. Well-differentiated Thyroid Cancer • No role for elective neck dissection • Central compartment, level VI nodal dissection for positive central nodes • Modified neck dissection, at least levels II-V for neck metastasis, to include level IIB • “Berry-picking” is not indicated

  38. Medullary Thyroid Carcinoma • Total thyroidectomy and central compartment dissection, level VI for most cases • Ipsilateral nodal dissection at least levels II-V if central compartment is N+

  39. Salivary Gland Carcinoma • No added survival benefit to elective neck dissection • However, significant rate of occult nodal positivity for high grade tumors (adenoid cystic, squamous cell, high grade mucoepidermoid, etc.) • Comprehensive (I-V) ipsilateral nodal dissection for N+ disease or high grade tumor • Selective, I-III dissection for radiosensitive histologies with N0 necks and/or high grade tumor

  40. Summary • Comprehensive neck dissection Levels I-V recommended for clinically N+ necks • Sacrifice of structures only if clinically involved by tumor • Staging/Selective neck dissection indicated for N0 necks, dependent on primary tumor site • Comprehensive neck dissection Levels I-V indicated for N2+ neck disease treated by chemoradiation

  41. Summary • The use of selective neck dissection for clinically N+ is controversial • The use of sentinel node biopsy is less sensitive that selective neck dissection, and remains investigational

  42. Future Trials: Statistical Consideration • Most retrospective trials describe a 5-10% difference in clinical endpoints in comparison of sentinel node biopsy, selective neck dissection, and comprehensive neck dissection • Assuming 80% power, would require a randomized trial with 1400 patients (700/arm) to detect a statistically significant 5% difference.

  43. Surgeons must be very careful,When they take the knife!Underneath their fine incisions,Stirs the Culprit Life! ~Emily Dickinson

More Related